FDA says Latvia’s OOO Elanders had inadequate seafood HACCP plans for ready-to-eat cold smoked mackerel and marinated herring.
What happened
FDA inspected OOO Elanders’ seafood processing facility in Riga, Latvia, on July 11 - 12, 2022, and issued an FDA-483 listing inspection observations. The company sent revised HACCP plans on August 15, 2022, for ready-to-eat refrigerated vacuum-packed cold smoked mackerel and refrigerated salted herring fillets in marinade solution. FDA found the revised plans still did not adequately identify hazards, set a critical control point for Clostridium botulinum, or set adequate critical limits for C. botulinum and histamine.
What FDA found
The revised HACCP plans did not list pathogen growth and toxin formation, including Staphylococcus aureus, or finfish allergen as food safety hazards, so required controls were missing.
21 CFR 123.6(a) and (c)(1)The mackerel plan did not identify a critical control point to control Clostridium botulinum growth and toxin formation at a processing step.
21 CFR 123.6(a) and (c)(2)Critical limits at a processing step were inadequate for Clostridium botulinum and histamine; for histamine, the plan did not include FDA’s recommended limit that previously frozen fish exposed to 21°C to 25°C should not exceed 12 hours.
21 CFR 123.6(c)(3)The pickup warehouse and storage critical limits were inadequate for histamine control; FDA recommends holding finished product at 40°F (4.4°C) or below.
21 CFR 123.6(c)(3)
What FDA wants
FDA asks OOO Elanders to respond in writing within 15 working days with specific corrections, a revised HACCP plan, and five consecutive days of completed monitoring records for five production date codes. If it cannot finish all corrections in that time, it must explain the delay and say when it will finish.
Who should pay attention
- U.S. importers of Latvian ready-to-eat seafood
- brands that buy cold smoked mackerel or marinated herring from this processor
- retailers and foodservice buyers of imported ready-to-eat seafood
This is a summary. Read the original letter on fda.gov.